Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/STK4_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/STK4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/STK4_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/STK4_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/STK4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00059773 | Prostate | BPH | glycogen metabolic process | 20/3107 | 72/18723 | 1.16e-02 | 4.70e-02 | 20 |
GO:200123319 | Prostate | Tumor | regulation of apoptotic signaling pathway | 137/3246 | 356/18723 | 1.01e-21 | 1.25e-18 | 137 |
GO:000609117 | Prostate | Tumor | generation of precursor metabolites and energy | 166/3246 | 490/18723 | 2.38e-19 | 1.23e-16 | 166 |
GO:003164719 | Prostate | Tumor | regulation of protein stability | 112/3246 | 298/18723 | 4.18e-17 | 1.18e-14 | 112 |
GO:001598017 | Prostate | Tumor | energy derivation by oxidation of organic compounds | 116/3246 | 318/18723 | 1.54e-16 | 3.54e-14 | 116 |
GO:005109819 | Prostate | Tumor | regulation of binding | 122/3246 | 363/18723 | 2.86e-14 | 3.63e-12 | 122 |
GO:005082119 | Prostate | Tumor | protein stabilization | 76/3246 | 191/18723 | 1.55e-13 | 1.73e-11 | 76 |
GO:006145816 | Prostate | Tumor | reproductive system development | 133/3246 | 427/18723 | 1.24e-12 | 1.15e-10 | 133 |
GO:009719119 | Prostate | Tumor | extrinsic apoptotic signaling pathway | 81/3246 | 219/18723 | 2.48e-12 | 2.20e-10 | 81 |
GO:004860815 | Prostate | Tumor | reproductive structure development | 131/3246 | 424/18723 | 3.48e-12 | 2.89e-10 | 131 |
GO:001605514 | Prostate | Tumor | Wnt signaling pathway | 131/3246 | 444/18723 | 1.16e-10 | 7.11e-09 | 131 |
GO:019873814 | Prostate | Tumor | cell-cell signaling by wnt | 131/3246 | 446/18723 | 1.61e-10 | 9.69e-09 | 131 |
GO:200123619 | Prostate | Tumor | regulation of extrinsic apoptotic signaling pathway | 59/3246 | 151/18723 | 1.86e-10 | 1.09e-08 | 59 |
GO:200123517 | Prostate | Tumor | positive regulation of apoptotic signaling pathway | 51/3246 | 126/18723 | 7.27e-10 | 3.59e-08 | 51 |
GO:003158916 | Prostate | Tumor | cell-substrate adhesion | 109/3246 | 363/18723 | 1.41e-09 | 6.71e-08 | 109 |
GO:004578519 | Prostate | Tumor | positive regulation of cell adhesion | 125/3246 | 437/18723 | 2.56e-09 | 1.08e-07 | 125 |
GO:003011114 | Prostate | Tumor | regulation of Wnt signaling pathway | 99/3246 | 328/18723 | 5.92e-09 | 2.34e-07 | 99 |
GO:001081018 | Prostate | Tumor | regulation of cell-substrate adhesion | 73/3246 | 221/18723 | 9.68e-09 | 3.62e-07 | 73 |
GO:005109919 | Prostate | Tumor | positive regulation of binding | 61/3246 | 173/18723 | 1.02e-08 | 3.79e-07 | 61 |
GO:000170115 | Prostate | Tumor | in utero embryonic development | 106/3246 | 367/18723 | 2.37e-08 | 8.09e-07 | 106 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STK4 | SNV | Missense_Mutation | | c.499N>C | p.Asp167His | p.D167H | Q13043 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
STK4 | SNV | Missense_Mutation | | c.1340N>C | p.Arg447Thr | p.R447T | Q13043 | protein_coding | deleterious(0) | possibly_damaging(0.71) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STK4 | SNV | Missense_Mutation | rs768691855 | c.1408N>T | p.Arg470Trp | p.R470W | Q13043 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STK4 | SNV | Missense_Mutation | | c.499G>A | p.Asp167Asn | p.D167N | Q13043 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A1IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
STK4 | insertion | Frame_Shift_Ins | novel | c.945_946insCAAACATT | p.Asp316GlnfsTer31 | p.D316Qfs*31 | Q13043 | protein_coding | | | TCGA-A8-A07O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | CR |
STK4 | insertion | In_Frame_Ins | novel | c.946_947insTGGCAGCTATAACATGTTCCCAAC | p.Asp316delinsValAlaAlaIleThrCysSerGlnHis | p.D316delinsVAAITCSQH | Q13043 | protein_coding | | | TCGA-A8-A07O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | CR |
STK4 | SNV | Missense_Mutation | novel | c.970G>A | p.Glu324Lys | p.E324K | Q13043 | protein_coding | tolerated(0.11) | benign(0.15) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
STK4 | SNV | Missense_Mutation | | c.535G>A | p.Ala179Thr | p.A179T | Q13043 | protein_coding | deleterious(0) | possibly_damaging(0.905) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
STK4 | SNV | Missense_Mutation | novel | c.1364N>C | p.Met455Thr | p.M455T | Q13043 | protein_coding | deleterious(0.01) | probably_damaging(0.965) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
STK4 | SNV | Missense_Mutation | | c.415N>C | p.Tyr139His | p.Y139H | Q13043 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-A6-6648-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6789 | STK4 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | inhibitor | 252827426 | | |
6789 | STK4 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | inhibitor | 178102336 | BOSUTINIB | |
6789 | STK4 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | inhibitor | 310264738 | CERDULATINIB | |
6789 | STK4 | KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | inhibitor | HESPERADIN | HESPERADIN | 19035792 |